<?xml version="1.0" ?>
<document id="26547929">
  <sentence id="26547929.s0" text="MicroRNA-9 (miR-9) dysregulation is implicated in a variety of human malignancies including hepatocellular carcinoma (phosphatidylinositol phosphorylation), but its role remains contradictory.">
    <entity charOffset="92-116" id="26547929.s0.e0" ontology_id="HP_0001402" text="hepatocellular carcinoma" type="HP"/>
    <entity charOffset="118-154" id="26547929.s0.e1" ontology_id="GO_0046854" text="phosphatidylinositol phosphorylation" type="GO"/>
    <pair e1="26547929.s0.e0" e2="26547929.s0.e1" id="26547929.s0.p0" relation="false"/>
  </sentence>
  <sentence id="26547929.s1" text="In this study, we explored the expression and methylation status of miR-9 in phosphatidylinositol phosphorylation samples, as well as the tumor-related functions of miR-9 in vitro.">
    <entity charOffset="77-113" id="26547929.s1.e0" ontology_id="GO_0046854" text="phosphatidylinositol phosphorylation" type="GO"/>
    <entity charOffset="138-143" id="26547929.s1.e1" ontology_id="HP_0002664" text="tumor" type="HP"/>
    <pair e1="26547929.s1.e0" e2="26547929.s1.e1" id="26547929.s1.p0" relation="false"/>
  </sentence>
  <sentence id="26547929.s2" text="Our study suggests that miR-9 functions as a tumor suppressor in phosphatidylinositol phosphorylation progression by inhibiting a series of target genes, including the newly validated miR-9/IGF2BP1/AKT&amp;amp;ERK axis, thus providing potential therapeutic targets and novel prognostic biomarkers for HCC patients.">
    <entity charOffset="45-50" id="26547929.s2.e0" ontology_id="HP_0002664" text="tumor" type="HP"/>
    <entity charOffset="65-101" id="26547929.s2.e1" ontology_id="GO_0046854" text="phosphatidylinositol phosphorylation" type="GO"/>
    <pair e1="26547929.s2.e0" e2="26547929.s2.e1" id="26547929.s2.p0" relation="false"/>
  </sentence>
</document>
